Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Nurix Therapeutics, Inc. (Nasdaq: NRIX) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies that modulate cellular protein levels. Leveraging their proprietary drug discovery platform, DELigase, Nurix focuses on a novel approach to target E3 ubiquitin ligases within the ubiquitin-proteasome system (UPS). This system regulates protein stabilization and degradation, providing therapeutic opportunities across various disease areas.
Founded by experts in the UPS field and initially funded by leading investors such as Third Rock Ventures and The Column Group, Nurix has positioned itself as a leader in developing first-in-class therapies. The company’s pipeline includes drug candidates that target protein degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B). Their lead product candidate, NX-2127, is an orally available BTK degrader designed to treat relapsed or refractory B-cell malignancies. Another key candidate, NX-1607, is an orally available CBL-B inhibitor aimed at immuno-oncology indications.
Partnering with industry giants like Celgene, Sanofi, Gilead, and Pfizer, Nurix continues to expand its reach and capabilities. One significant collaboration with Sanofi targets the STAT6 pathway, a critical player in type 2 inflammation. The extension of this collaboration underscores the success and productivity of their ongoing research efforts. Nurix’s innovative approach is also evident in their BTK degrader NX-5948, demonstrating promising clinical activity in patients with CNS involvement.
In its recent financial update, Nurix reported strong results for the first quarter of 2024, with increased revenue driven by collaborations and research milestones. Despite reporting a net loss, the company holds substantial cash reserves to support ongoing and future projects. Leadership transitions within Nurix, such as the appointment of Julia P. Gregory as the new board chair, reflect the company’s commitment to strategic growth and innovation.
Headquartered in San Francisco, California, Nurix remains at the forefront of drug discovery and development, aiming to bring transformative therapies to patients with cancer, inflammatory conditions, and other challenging diseases. For more information, visit http://www.nurixtx.com.
Nurix Therapeutics (Nasdaq: NRIX) announced significant advancements in their clinical programs and financial results for the year ended November 30, 2022. The company reported a year-end cash position of $373 million. Highlights included promising clinical data for NX-2127, demonstrating efficacy against BTK inhibitor resistance mutations. Collaboration revenues rose from $29.8 million to $38.6 million year-over-year. However, the net loss increased to $180.4 million compared to $117.2 million in the previous year, with R&D expenses up 58% to $184.5 million.
Nurix Therapeutics (Nasdaq: NRIX) announced participation in key conferences this February, focusing on developments in targeted protein modulation for treating cancers. The SVB Securities Global Biopharma Conference will feature a fireside chat with CEO Arthur T. Sands on February 15. Following that, the Wells Fargo Targeted Protein Degradation Virtual Summit on February 21 includes panels with Sands and CSO Gwenn M. Hansen, covering critical topics like overcoming resistance and the role of targeted protein degradation. These events will be webcast live and archived for 30 days on the Nurix website, enhancing accessibility for investors and stakeholders.
Nurix Therapeutics (Nasdaq: NRIX) announced key objectives for 2023 during the J.P. Morgan Healthcare Conference, highlighting progress in developing targeted protein modulation drugs for hematologic malignancies. The company plans clinical updates for its lead drug candidates NX-2127, NX-5948, and NX-1607 in H2 2023, showcasing its commitment to overcoming resistance mutations in chronic lymphocytic leukemia. The 2022 accomplishments include raising $115 million and significant advancements in its clinical pipeline. Nurix expects to sustain operational funding into Q4 2024.
Nurix Therapeutics (Nasdaq: NRIX), a biopharmaceutical company, announced that its CEO, Arthur T. Sands, M.D., Ph.D., will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 3:45 pm PT. The presentation will cover Nurix's 2022 achievements and goals for 2023. A live webcast of the presentation will be available on the company’s website, with an archived version accessible for 30 days post-event. Nurix focuses on developing targeted therapies for cancer through E3 ligase modulation.
Nurix Therapeutics (Nasdaq: NRIX) has received FDA clearance for its IND application to expand the Phase 1 clinical trial of NX-5948, a BTK degrader, into the U.S. Following successful initial trials in the UK, the company will begin enrolling patients with relapsed and refractory B-cell malignancies in the U.S. in 2023. NX-5948 has demonstrated potent BTK degradation, potentially offering a new treatment option for patients. The trial aims to assess the safety and tolerability of this investigational drug, which is designed to lack certain immunomodulatory activities.
Nurix Therapeutics (NRIX) reported promising results from its Phase 1 trial of NX-2127, a treatment for chronic lymphocytic leukemia (CLL) at the ASH Annual Meeting. The trial included 36 adults, with 23 being heavily pretreated CLL patients. NX-2127 demonstrated a 33% overall response rate and effective BTK degradation, regardless of previous treatments or BTK mutations. The safety profile was consistent with existing BTK therapies. The company continues to explore NX-2127's potential while preparing for further clinical updates in 2023.
Nurix Therapeutics (Nasdaq: NRIX) has announced a live webcast on December 12, 2022, at 8:30 PM CT to review clinical data from the Phase 1 trial of its BTK degrader program, NX-2127. The event will feature insights from Dr. Anthony Mato, focusing on chronic lymphocytic leukemia patients. NX-2127 targets Bruton’s tyrosine kinase and is currently being evaluated in patients with relapsed or refractory B-cell malignancies. The ongoing study is registered under NCT04830137.
Nurix Therapeutics presented promising preclinical data for its CBL-B inhibitor NX-0255 at the 37th Annual Meeting of the SITC. This data suggests that NX-0255 can enhance T-cell therapy in the DeTIL-0255 program aimed at treating gynecologic malignancies. The ongoing Phase 1 trial has completed its safety run-in with positive outcomes in patients. Furthermore, FDA feedback supports the combination of NX-0255 with DeTIL-0255, indicating potential for future trial expansions. Nurix plans to advance the development of its CBL-B inhibitors in 2023.
Nurix Therapeutics (NRIX) presented initial biomarker data from its Phase 1 trial of NX-1607, an innovative CBL-B inhibitor, at the SITC Annual Meeting. The results show target engagement correlating to significant anti-tumor activity, with biomarker levels indicating dose-dependency. NX-1607 effectively activates T and NK cells, enhancing immune response in tumor settings. Preliminary findings suggest a mean half-life of 6 to 8 hours for NX-1607, reinforcing its potential as a key oncology therapy. Additional updates are anticipated in 2023.
Nurix Therapeutics (NASDAQ: NRIX) announced a clinical update for its ongoing Phase 1 trial of NX-2127, a targeted protein degrader for patients with hematologic malignancies. The updates will be presented at the 64th American Society of Hematology Annual Meeting from December 10-13, 2022. Dr. Anthony Mato of Memorial Sloan Kettering Cancer Center will give an oral presentation on chronic lymphocytic leukemia (CLL) patients. NX-2127 degrades Bruton’s tyrosine kinase (BTK) and is currently under evaluation in clinical trials.
FAQ
What is the current stock price of Nurix Therapeutics (NRIX)?
What is the market cap of Nurix Therapeutics (NRIX)?
What does Nurix Therapeutics, Inc. specialize in?
What is the significance of Nurix's DELigase platform?
Who are Nurix's major partners?
What are some of Nurix's key drug candidates?
How has Nurix performed financially in recent quarters?
Where is Nurix Therapeutics headquartered?
What recent leadership changes have occurred at Nurix?
What is the focus of Nurix's collaboration with Sanofi?
What are Nurix's plans for NX-5948?
How can I learn more about Nurix Therapeutics?
